ArticleCartilage
Evaluation of the Anti-Inflammatory and Chondroprotective Effect of Celecoxib on Cartilage
Article in Cartilage. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- A microenvironment-responsive microsphere-PLGA-PEG-PLGA hydrogel for sustained and coordinated co-delivery of celecoxib and ropivacaine in osteoarthritis therapy.Drug delivery and translational research · 2026Article
- Intra-Articular Cyclo(His-Pro) Attenuates Monosodium Iodoacetate-Induced Osteoarthritis by Suppressing COX-2/PGEInternational journal of molecular sciences · 2026Article
- Celecoxib and shikonin loaded dissolving microneedle exert analgesic, anti-inflammatory and chondroprotective activity for osteoarthritis treatment.Frontiers in cell and developmental biology · 2026Article
- Microenvironmental response-based treatment of osteoarthritis is a highly effective and durable program: a review.Journal of orthopaedic surgery and research · 2025Review
- Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.Pharmaceutics · 2025Review
- The Role of PGE2 in Age-related Diseases.Current drug targets · 2025Review
- Cell-imprinted substrates as biomimetic platforms for osteoarthritis modeling with mesenchymal stem cells.BioImpacts : BI · 2025Article
- Inflammation as a therapeutic target for osteoarthritis: A literature review of clinical trials.Clinical rheumatology · 2024Review
- Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition.American journal of clinical and experimental urology · 2024Review
- Revealing Changes in Celecoxib Nanostructured Lipid Carrier's Bioavailability Using Hyaluronic Acid as an Enhancer by HPLC-MS/MS.Drug design, development and therapy · 2024Article
- Repair of full-thickness articular cartilage defects with a 3DP-anchored three-phase complex.Heliyon · 2023Article
- Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) reveals potential lipid markers between infrapatellar fat pad biopsies of osteoarthritis and cartilage defect patients.Analytical and bioanalytical chemistry · 2023Article
- Engineered biochemical cues of regenerative biomaterials to enhance endogenous stem/progenitor cells (ESPCs)-mediated articular cartilage repair.Bioactive materials · 2023Review
- BURN-SYNOVECTOMY MOUSE MODEL FOR TEMPOROMANDIBULAR JOINT OSTEOARTHRITIS.European cells & materialsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe potential chondroprotective effect of celecoxib, a nonsteroidal anti-inflammatory drug and selective cyclooxygenase-2 inhibitor used to reduce pain and inflammation in knee osteoarthritis patients, is disputed. This study aimed at investigating the chondroprotective effects of celecoxib on (1) human articular cartilage explants and (2) in an
designArticular cartilage explants from 16 osteoarthritis patients were cultured for 24 hours with celecoxib or vehicle. Secreted prostaglandins (prostaglandin E
resultsSecretion of prostaglandins, target of Nesh-SH3 (ABI3BP), and osteonectin proteins decreased, whereas tissue inhibitor of metalloproteinase 2 (TIMP-2) increased significantly after celecoxib treatment in the human (
conclusionsOur data demonstrated that celecoxib acts chondroprotective on cartilage
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.